Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQH2929 in Acute Exacerbations of Generalized Pustular Psoriasis
NCT07314060Phase 2
Key facts
- Status
- Terminated
- Start
- Mar 2026
- Primary completion
- Jul 2026
- Countries
- 1
- Modality
- Small Molecules, Monoclonal Antibodies
- Drugs
- TQH2929
- Conditions
- generalized pustular psoriasis (GPP)
01
Overview
Phase 2, randomised, double-blind trial in generalized pustular psoriasis (GPP) comparing TQH2929 Injections with TQH2929 Placebo (2 arms). Primary endpoint: Percentage of patients with a score of 0 for the pustule subterm at 1 week. Started Mar 2026; status: terminated.
02
Design
2 arms- Study design
- RandomizedDouble-blind
TQH2929 Injections
Intravenous infusion, single dose of TQH2929
TQH2929 Placebo
Intravenous infusion, single dose of Placebo
03
Who it enrols
Adults aged 18-75 with acute exacerbations of generalized pustular psoriasis, excluding those with active infections, history of malignancies, or recent major surgeries/blood transfusions.
04
Endpoints
Primary
Percentage of patients with a score of 0 for the pustule subterm
Secondary
Percentage of patients with a Generalized Pustular Psoriasis Physician Global Assessment total score of 0 or 1
Percentage change from baseline in Generalized Pustular Psoriasis Area and Severity Index total score
Change from baseline in Generalized Pustular Psoriasis Area and Severity Index total score
Percentage of patients with Generalized Pustular Psoriasis Area and Severity Index 50
Percentage of patients with Generalized Pustular Psoriasis Area and Severity Index 75
Percentage of patients with pustule subterm achieving a score of 0
Change from baseline in Psoriasis Symptom Scale score
Change from baseline in disease life quality index
Beyond the preview
Go deeper on NCT07314060.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07314060.